IRES

HKTDC's major focus areas promote Hong Kong's advantages

Retrieved on: 
Wednesday, February 21, 2024

HONG KONG, Feb 21, 2024 - (ACN Newswire) - The Hong Kong Trade Development Council (HKTDC) today announced its major focus areas for 2024-2025, which strengthen Hong Kong's status as a leading global business and investment hub and convention and exhibition (C&E) centre.

Key Points: 
  • HONG KONG, Feb 21, 2024 - (ACN Newswire) - The Hong Kong Trade Development Council (HKTDC) today announced its major focus areas for 2024-2025, which strengthen Hong Kong's status as a leading global business and investment hub and convention and exhibition (C&E) centre.
  • The HKTDC is committed to promoting Hong Kong's advantages internationally and creating opportunities for Hong Kong businesses.
  • Looking ahead, we will further consolidate Hong Kong's status as an international financial, trade and international C&E centre and promote Hong Kong's strengths internationally.
  • - We will deepen collaboration with R&D and innovation centres of Hong Kong-based universities to promote technology commercialisation with a focus on healthtech.

VISION OUTLINES ITS OBJECTIONS TO THE ISS REPORT REGARDING THE UPCOMING IRES EGM AND STRONGLY ENCOURAGES INVESTORS TO VOTE "FOR" THE RESOLUTIONS PUT FORTH BY VISION

Retrieved on: 
Monday, February 5, 2024

DUBLIN, Feb. 5, 2024 /PRNewswire/ -- Vision Capital Corporation, together with its affiliates, (collectively referred to as "Vision") a significant shareholder of Irish Residential Properties REIT plc (ISE: IRES) – ("IRES," the "REIT", or the "Company"), owning over 26 million ordinary shares representing approximately 5.01% of IRES' ordinary shares, is disappointed and concerned with the ISS Analysis1 utilised in the Institutional Shareholder Services' ("ISS") report released on February 1st, 2024, pertaining to the upcoming IRES extraordinary general meeting (the "ISS Report") and hence objects to the conclusions ISS has reached.

Key Points: 
  • This includes the support of Canadian Apartment Properties REIT, which is both the founding and largest shareholder of IRES.
  • Vision reminds IRES' shareholders that if they wish to see meaningful change at IRES to maximise value for all of IRES' shareholders, they should vote "FOR" all the resolutions put forth by Vision.
  • Neither IRES nor ISS, as discussed in the ISS Analysis, recognise this fact.
  • Any failure to comply with the restrictions may constitute a violation of the securities law of any such jurisdiction.

Commencement of Strategic Review

Retrieved on: 
Monday, January 8, 2024

The Company today announces that the Board of Directors of I-RES (the “Board”) has decided to commence a strategic review to consider and evaluate all strategic options that may be available to maximise and unlock value for shareholders in the Company (the “Strategic Review”).

Key Points: 
  • The Company today announces that the Board of Directors of I-RES (the “Board”) has decided to commence a strategic review to consider and evaluate all strategic options that may be available to maximise and unlock value for shareholders in the Company (the “Strategic Review”).
  • This Strategic Review will commence as soon as practicable in Q1 2024, following the release of the Company’s 2023 Full Year Financial Results.
  • The Special Committee will retain specialist international financial and real estate advice to assist with the Strategic Review.
  • There is no certainty that any change will result from the Strategic Review or that any sale, strategic investment or other transaction will be concluded, nor as to the terms on which any offer, strategic investment or other transaction may be made.

GenScript ProBio Partners With NuclixBio to Pave the Way for South Korea’s First Large-scale Production Process for “Circular RNA Therapeutics”

Retrieved on: 
Thursday, November 9, 2023

GenScript ProBio, a global multimodality CDMO and NuclixBio, a company developing treatments based on circular RNA, announced on 9th Nov that they have entered into a strategic business agreement to develop the first circular RNA-based anticancer drug in South Korea.

Key Points: 
  • GenScript ProBio, a global multimodality CDMO and NuclixBio, a company developing treatments based on circular RNA, announced on 9th Nov that they have entered into a strategic business agreement to develop the first circular RNA-based anticancer drug in South Korea.
  • With this strategic partnership, both companies will establish the first large-scale production process for circular RNA therapeutics in South Korea from preclinical to clinical stages (with GMP production).
  • This also serves as a cornerstone for NuclixBio's of its circular RNA-based immune cancer treatment to enter full-scale clinical trials.
  • Not only preventive vaccines but also cancer vaccines, immune anticancer drugs, CAR-T, and other areas are seeing mRNA therapy development.

Orna Therapeutics Unveils Progress of Circular RNA Platform and Improvements in Lead Program ORN-101 at PEGS and ASGCT

Retrieved on: 
Thursday, May 18, 2023

CAMBRIDGE, Mass., May 18, 2023 /PRNewswire/ -- Orna Therapeutics, a biotechnology company pioneering a new investigational class of engineered circular RNA (oRNA) therapies, presented data on the progress of lead program ORN-101, a development-stage in situ CAR program, at the Protein Engineering Summit (PEGS) and at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting in Los Angeles.

Key Points: 
  • The presentations include a session and talk at PEGS, as well as a poster presentation at ASGCT, which may be viewed on the Orna website here .
  • "Using the Orna FoRCE platform, we've been able to develop ORN-101, a potent anti-cancer circular RNA therapy delivered via LNP," said Robert Mabry, PhD, Chief Scientific Officer at Orna.
  • These desirable features further allow oRNA therapeutics to be developed for applications beyond infectious disease, including oncology and genetic disorders.
  • ORN-101 features high expression of the CAR driven by an optimized IRES element, selected by Orna's FoRCE platform to yield durable protein expression.

Orna Therapeutics to Present Progress of Lead Program ORN-101 at PEGS and ASGCT

Retrieved on: 
Thursday, May 4, 2023

CAMBRIDGE, Mass., May 4, 2023 /PRNewswire/ -- Orna Therapeutics, a biotechnology company pioneering a new investigational class of engineered circular RNA (oRNA) therapies, today announced two presentations at the Protein Engineering Summit (PEGS) taking place May 15-19 in Boston as well as a poster presentation at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting in Los Angeles May 16-20. Orna is presenting preclinical results for ORN-101, an in situ CAR program in development, as well as further details about its platform.

Key Points: 
  • Orna is presenting preclinical results for ORN-101, an in situ CAR program in development, as well as further details about its platform.
  • "We are paving the way for advancements in RNA therapeutics that reach beyond infectious disease to treat cancer and genetic disorders," Robert Mabry, PhD, Chief Scientific Officer at Orna.
  • "Our ORN-101 program demonstrates the benefits of our platform's ability to create a paradigm-changing treatment with the characteristics we believe matter most to patients, including a rapid timeline from diagnosis to treatment, strong expression and tumor-killing potency at low dose, and a regimen without the harsh chemotherapeutic lymphodepletion protocols typically required for standard engineered cell therapies."
  • Details for the presentations are as follows:

Ewing Morris Supports Vision Capital's Quest for Change at IRES

Retrieved on: 
Tuesday, April 25, 2023

TORONTO, April 25, 2023 /PRNewswire/ -- Ewing Morris & Co. Investment Partners Ltd. ("Ewing Morris") has been a shareholder of Irish Residential Properties REIT ("IRES") since January 2021.

Key Points: 
  • TORONTO, April 25, 2023 /PRNewswire/ -- Ewing Morris & Co. Investment Partners Ltd. ("Ewing Morris") has been a shareholder of Irish Residential Properties REIT ("IRES") since January 2021.
  • We have reviewed the letter issued by Vision Capital and share many of their concerns, specifically regarding the viability of IRES as a functioning public company.
  • We have advised the board of IRES of our dissatisfaction, to which we received no response.
  • Ewing Morris will vote consistently with Vision's recommendations against certain directors and board proposals.

CAPREIT ADVISES VISION THAT IT WILL VOTE ITS IRES SHARES CONSISTENTLY WITH VISION AGAINST CERTAIN IRES DIRECTORS AND AGAINST THREE OTHER RESOLUTIONS

Retrieved on: 
Tuesday, April 25, 2023

In the press releases of the open letters to IRES shareholders issued by Vision on April 12 and April 24, 2023, Vision indicated that it will be voting against Resolutions 2a, 2c, 2d, 2g, 6, 8a, and 8b at the AGM.

Key Points: 
  • In the press releases of the open letters to IRES shareholders issued by Vision on April 12 and April 24, 2023, Vision indicated that it will be voting against Resolutions 2a, 2c, 2d, 2g, 6, 8a, and 8b at the AGM.
  • Furthermore, Vision will also be voting against the re-election of Margaret Sweeney as Director (Resolution 2b).
  • Vision asks that shareholders vote on these resolutions in the same way.
  • Vision owns approximately 5.0% of the IRES ordinary shares.

HKTDC takes Building for the Future campaign to Indonesia

Retrieved on: 
Tuesday, February 28, 2023

The "Building for the Future" promotion was held in Indonesia for the first time, with the highlighted "Hong Kong Forum on Urban Development" attracting more than 300 representatives from Indonesian government departments and businesses.

Key Points: 
  • The "Building for the Future" promotion was held in Indonesia for the first time, with the highlighted "Hong Kong Forum on Urban Development" attracting more than 300 representatives from Indonesian government departments and businesses.
  • Dr Ir Herry Trisa Putra Zuna, Directorate General of Ministry of Public Works and Housing, Republic of Indonesia, gave remarks at the Forum.
  • It introduced the strengths and value-added services of Hong Kong IRES and explored collaboration opportunities between Indonesia and Hong Kong in infrastructure development projects.
  • Since the launch of the Building for the Future campaign in 2015, the HKTDC has led Hong Kong urban development services missions to eight cities in Mainland China and Kuala Lumpur, Malaysia.

Trading Update and Notice of Results

Retrieved on: 
Sunday, January 22, 2023

Irish Residential Properties REIT plc (the "Company" or "IRES"), Ireland’s largest provider of private rental accommodation with a portfolio of 3,938 homes, today provides an update on trading for the year ended 31 December 2022 ahead of the publication of its full year results on Friday 24 February 2023.

Key Points: 
  • Irish Residential Properties REIT plc (the "Company" or "IRES"), Ireland’s largest provider of private rental accommodation with a portfolio of 3,938 homes, today provides an update on trading for the year ended 31 December 2022 ahead of the publication of its full year results on Friday 24 February 2023.
  • Demand for IRES properties continues to far outstrip supply, with occupancy of 99.4% as at 31 December 2022, (99.1% at 31 December 2021).
  • The Company retains its strong financial position, with a robust balance sheet and ample liquidity.
  • The underlying business maintained a strong performance during the second half of the year amid a challenging market environment.